These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20404384)

  • 41. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
    Michos ED; Blumenthal RS
    J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A tale of three labels: translating the JUPITER trial data into regulatory claims.
    Ridker PM
    Clin Trials; 2011 Aug; 8(4):417-22. PubMed ID: 21835857
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular health. Statin therapy reduces disease in healthy volunteers--but how, exactly?
    Couzin J
    Science; 2008 Nov; 322(5904):1039. PubMed ID: 19008423
    [No Abstract]   [Full Text] [Related]  

  • 44. Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice.
    Motsko SP; Russmann S; Ming EE; Singh VP; Vendiola RM; Jones JK
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1214-22. PubMed ID: 19780020
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rosuvastatin in patients with elevated C-reactive protein.
    Pierard LA
    N Engl J Med; 2009 Mar; 360(10):1040; author reply 1041-2. PubMed ID: 19271277
    [No Abstract]   [Full Text] [Related]  

  • 46. Rosuvastatin in patients with elevated C-reactive protein.
    Gibbons RJ
    N Engl J Med; 2009 Mar; 360(10):1038; author reply 1041-2. PubMed ID: 19264695
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
    Nicholls SJ; Uno K; Kataoka Y
    Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1383-90. PubMed ID: 22059787
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary prevention with statins is more cost-effective.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(2):102. PubMed ID: 21556457
    [No Abstract]   [Full Text] [Related]  

  • 49. [JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
    Lubsen J
    Ned Tijdschr Geneeskd; 2009 Feb; 153(6):216-7. PubMed ID: 19271438
    [No Abstract]   [Full Text] [Related]  

  • 50. JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
    Cardiovasc J Afr; 2009; 20(3):211. PubMed ID: 19575096
    [No Abstract]   [Full Text] [Related]  

  • 51. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rosuvastatin in patients undergoing hemodialysis.
    Ganguli A
    N Engl J Med; 2009 Jul; 361(1):93; author reply 94-5. PubMed ID: 19571292
    [No Abstract]   [Full Text] [Related]  

  • 53. Rosuvastatin in patients with elevated C-reactive protein.
    Chan PS; Nallamothu BK; Hayward RA
    N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271273
    [No Abstract]   [Full Text] [Related]  

  • 54. High-sensitivity C-reactive protein, obesity, and subclinical atherosclerosis: implications of JUPITER from the MESA study.
    Targher G
    Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1251-2. PubMed ID: 21593456
    [No Abstract]   [Full Text] [Related]  

  • 55. Extreme all-cause mortality in JUPITER requires reexamination of vital records.
    Serebruany VL
    Cardiology; 2011; 120(2):84-8. PubMed ID: 22142620
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rosuvastatin in patients with elevated C-reactive protein.
    Mak KH; Chan ES
    N Engl J Med; 2009 Mar; 360(10):1039-40; author reply 1041-2. PubMed ID: 19271274
    [No Abstract]   [Full Text] [Related]  

  • 57. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Fonseca FA; Izar MC
    Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FDA approves a statin therapy for some: certain, asymptomatic individuals targeted.
    Mitka M
    JAMA; 2010 Apr; 303(13):1242-3. PubMed ID: 20371776
    [No Abstract]   [Full Text] [Related]  

  • 59. Statins induce hyperglycaemia of uncertain importance.
    Montori VM; Brito JP
    Evid Based Med; 2013 Aug; 18(4):157-8. PubMed ID: 23125233
    [No Abstract]   [Full Text] [Related]  

  • 60. Statins work around the world.
    Postmus I; Trompet S; Wouter Jukema J
    Curr Med Res Opin; 2013 Jul; 29(7):747-9. PubMed ID: 23614629
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.